Discovery of a novel series of Chk1 kinase inhibitors with a distinctive hinge binding mode

ACS Medicinal Chemistry Letters

Volumn 3, Issue 2, 2012, Pages 123-128

  Huang, Xiaohua ^a   Cheng, Cliff C ^a   Fischmann, Thierry O ^a   Duca, José S ^a,b   Yang, Xianshu ^a   Richards, Matthew ^a   Shipps, Gerald W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

affinity selection?mass spectrometry (AS MS); Automated Ligand Identification System (ALIS); CHK1 protein kinase; structure based drug design; thiazole 4 carboxamide

Indexed keywords

2 ARYL N [2 (PIPERAZIN 1 YL)PHENYL]THIAZOLE 4 CARBOXAMIDE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; LIGAND BINDING; MASS SPECTROMETRY; NANOANALYSIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 84863166046     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200249h     Document Type: Article

References (34)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global Cancer Statistics CA Cancer J. Clin. 2011, 61, 69
2. Hurley, L. H. DNA and its associated processes as targets for cancer therapy Nat. Rev. Cancer 2002, 2, 188
3. Zhou, B.-B. S.; Elledge, S. J. The DNA damage response: Putting checkpoints in perspective Nature 2000, 408, 433
4. Kawabe, T. G2 checkpoint abrogators as anticancer drugs Mol. Cancer Ther. 2004, 3, 513
5. Xiao, Z.; Chen, Z.; Gunasekera, A. H.; Sowin, T. J.; Rosenberg, S. H.; Fesik, S.; Zhang, H. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents J. Biol. Chem. 2003, 278, 21767
6. Cho, S. H.; Toouli, C. D.; Fujii, G. H.; Crain, C.; Parry, D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint Cell Cycle 2005, 4, 131
7. Arrington, K. L.; Dudkin, V. Y. Novel inhibitors of checkpoint kinase 1 ChemMedChem 2007, 2, 1571
8. Ashwell, S.; Janetka, J. W.; Zabludoff, S. Keeping checkpoint kinases in line: New selective inhibitors in clinical trials Expert Opin. Invest. Drugs 2008, 17, 1331
9. Blasina, A.; Hallin, J.; Chen, E.; Arango, M. E.; Kraynov, E.; Register, J.; Grant, S.; Ninkovic, S.; Chen, P.; Nichols, T.; O'Connor, P.; Anderes, K. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 Mol. Cancer Ther. 2008, 7, 2394
10. Zabludoff, S. D.; Deng, C.; Grondine, M. R.; Sheehy, A. M.; Ashwell, S.; Caleb, B. L.; Green, S.; Haye, H. R.; Horn, C. L.; Janetka, J. W.; Liu, D.; Mouchet, E.; Ready, S.; Rosenthal, J. L.; Queva, C.; Schwartz, G. K.; Taylor, K. J.; Tse, A. N.; Walker, G. E.; White, A. M. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol. Cancer Ther. 2008, 7, 2955
11. Guzi, T. J.; Paruch, K.; Dwyer, M. P.; Labroli, M.; Shanahan, F.; Davis, N.; Taricani, L.; Wiswell, D.; Seghezzi, W.; Penaflor, E.; Bhagwat, B.; Wang, W.; Gu, D.; Hsieh, Y.; Lee, S.; Ming Liu, M.; Parry, D. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening Mol. Cancer Ther. 2011, 10, 591
12. Annis, A.; Chuang, C.-C.; Nazef, N. ALIS: An Affinity Selection-Mass Spectrometry System for the Discovery and Characterization of Protein-Ligand Interactions. In Methods and Principles in Medicinal Chemistry; Wanner, K.; Höfner, G., Eds.; Mass Spectrometry in Medicinal Chemistry: Applications in Drug Discovery; Mannhold, R.; Kubinyi, H.; Folkers, G., Series Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2007; Vol. 36, Chapter 3.
13. Annis, D. A.; Athanasopoulos, J.; Curran, P. J.; Felsch, J. S.; Kalghatgi, K.; Lee, W. H.; Nash, H. M.; Orminati, J.-P. A.; Rosner, K. E.; Shipps, G. W., Jr.; Thaddupathy, G. R. A.; Tylera, A. N.; Vilenchik, L.; Wagner, C. R.; Wintner, E. A. An affinity selection-mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial libraries Discovery of a novel antagonist of E. coli dihydrofolate reductase Int. J. Mass Spectrom. 2004, 238, 77
14. Cheng, C. C.; Shipps, G. W., Jr.; Yang, Z.; Sun, B.; Kawahata, N.; Soucy, K. A.; Soriano, A.; Orth, P.; Xiao, L.; Mann, P.; Black, T. Discovery and optimization of antibacterial AccC inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 6507
15. Cheng, C. C.; Huang, X.; Shipps, G. W., Jr.; Wang, Y.-S.; Wyss, D. F.; Soucy, K. A.; Jiang, C.-k.; Agrawal, S.; Ferrari, E.; He, Z.; Huang, H.-C. Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase ACS Med. Chem. Lett. 2010, 1, 466
16. Cheng, C. C.; Shipps, G. W., Jr.; Yang, Z.; Kawahata, N.; Lesburg, C. A.; Duca, J. S.; Bandouveres, J.; Bracken, J. D.; Jiang, C.-k.; Agrawal, S.; Ferrari, E.; Huang, H.-C. Inhibitors of hepatitis C virus polymerase: Synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2- yl)-benzamides Bioorg. Med. Chem. Lett. 2010, 20, 2119
17. Shipps, G. W., Jr.; Deng, Y.; Wang, T.; Popovici-Muller, J.; Curran, P. J.; Rosner, K. E.; Cooper, A. B.; Girijavallabhan, V.; Butkiewicz, N.; Cable, M. Aminothiazole inhibitors of HCV RNA polymerase Bioorg. Med. Chem. Lett. 2005, 15, 115
18. Annis, D. A.; Shipps, G. W., Jr.; Deng, Y.; Popovici-Müller, J.; Siddiqui, M. A.; Curran, P. J.; Gowen, M.; Windsor, W. T. Method for quantitative protein-ligand affinity measurements in compound mixtures Anal. Chem. 2007, 79, 4538
19. Lahue, B. R.; Ma, Y.; Shipps, G. W., Jr.; Seghezzi, W.; Herbst, R. Substituted benzimidazoles: a novel chemotype for small molecule h ksp inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 3405
20. Lan, H.; Cheng, C. C.; Kowalski, T. J.; Pang, L.; Shan, L.; Chuang, C.-C.; Jackson, J.; Rojas-Triana, A.; Bober, L.; Liu, L.; Voigt, J.; Orth, P.; Yang, X.; Shipps, G. W., Jr.; Hedrick, J. A. Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity J. Lipid Res. 2011, 52, 646
21. Annis, D. A.; Cheng, C. C.; Chuang, C.-C.; McCarter, J. D.; Nash, H. M.; Nazef, N.; Rowe, T.; Kurzeja, R. J. M.; Shipps, G. W., Jr. Inhibitors of the lipid phosphatase SHIP2 discovered by high throughput affinity selection-mass spectrometry screening of combinatorial libraries Comb. Chem. High Throughput Screen. 2009, 12, 760
22. Huang, X.; Shipps, G. W., Jr.; Cheng, C. C.; Spacciapoli, P.; Zhang, X.; McCoy, M. A.; Wyss, D. F.; Yang, X.; Achab, A.; Soucy, K.; Montavon, D. K.; Murphy, D. M.; Whitehurst, C. E. Discovery and hit-to-lead optimization of non-ATP competitive MK2 (MAPKAPK2) inhibitors ACS Med. Chem. Lett. 2011, 2, 632
23. Rosner, K. E.; Guo, Z.; Orth, P.; Shipps, G. W., Jr.; Belanger, D. B.; Chan, T. Y.; Curran, P. J.; Dai, C.; Deng, Y.; Girijavallabhan, V. M.; Hong, L.; Lavey, B. J.; Lee, J. F.; Li, D.; Liu, Z.; Popovici-Muller, J.; Ting, P. C.; Vaccaro, H.; Wang, L.; Wang, T.; Yu, W.; Zhou, G.; Niu, X.; Sun, J.; Kozlowski, J. A.; Lundell, D. J.; Madison, V.; McKittrick, B.; Piwinski, J. J.; Shih, N.-Y.; Siddiqui, M. A.; Strickland, C. O. The discovery of novel tartrate-based TNF-α converting enzyme (TACE) inhibitors Bioorg. Med. Chem. Lett. 2009, 20, 1189
24. 2 acetylcholine receptor ligands by affinity selection-mass spectrometry J. Biomol. Screen. 2006, 11, 194
25. Meikrantz, W.; Schlegel, R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases J. Biol. Chem. 1996, 271, 10205
26. Sampath, D.; Shi, Z.; Plunkett, W. Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine Mol. Pharmacol. 2002, 62, 680
27. Annis, D. A.; Nazef, N.; Chuang, C.-C.; Scott, M. P.; Nash, H. M. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures J. Am. Chem. Soc. 2004, 126, 15495
28. Zhao, L.; Curran, P. J.; Belanger, D. B.; Hamann, B.; Reddy, P. A.; Paruch, K.; Guzi, T. J.; Dwyer, M. P.; Siddiqui, M. A.; Tadikonda, P. K. Imidazopyrazines as protein kinase inhibitors. WO 2007/058942 A2.
29. Pierce, A. C.; Sandretto, K. L.; Bemis, G. W. Kinase inhibitors and the case for CH⋯O hydrogen bonds in protein-ligand binding Proteins: Struct. Funct. Genet 2002, 49, 567
30. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry J. Med. Chem. 2010, 53, 2601
31. Barillari, C.; Taylor, J.; Viner, R.; Essex, J. W. Classification of water molecules in protein binding sites J. Am. Chem. Soc. 2007, 129, 2577
32. Dwyer, M. P.; Paruch, K.; Labroli, M.; Alvarez, C.; Keertikar, K. M.; Poker, C.; Rossman, R.; Fischmann, T. O.; Duca, J. S.; Madison, V.; Parry, D.; Davis, N.; Seghezzi, W.; Wiswell, D.; Guzi, T. J. Discovery of pyrazolo[1,5- a ]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 1 Bioorg. Med. Chem. Lett. 2011, 21, 467
33. Billingsley, K. L.; Anderson, K. W.; Buchwald, S. L. A highly active catalyst for Suzuki-Miyaura cross-coupling reactions of heteroaryl compounds Angew. Chem., Int. Ed. 2006, 45, 3484
34. Gelman, D.; Buchwald, S. L. Efficient palladium-catalyzed coupling of aryl chlorides and tosylates with terminal alkynes: Use of a copper cocatalyst inhibits the reaction Angew. Chem., Int. Ed. 2003, 42, 5993